32家公募机构旗下46只权益产品今年以来净值翻倍

Core Insights - The performance of equity funds has significantly improved in 2023, with 96.58% of 7982 equity funds achieving net value growth, compared to only 18.63% in the same period last year [1] - A total of 46 equity funds have seen their net value double, with notable contributions from various fund management companies focusing on technology and healthcare sectors [1][2] Group 1: Fund Performance - As of September 23, 2023, 7709 out of 7982 equity funds have reported net value growth, marking a substantial increase in performance compared to the previous year [1] - The number of "doubling funds" with over 100% net value growth has reached 46, indicating strong market interest and investment returns [1] Group 2: Sector Focus - Several funds have achieved remarkable results by investing in the technology sector, particularly in AI and cloud computing, with the top-performing fund showing a 201.63% net value growth [1] - Funds such as Huatai-PB Quality Selected Mixed and Xinao Performance Driven Mixed are also focusing on AI, while others like Bank of China Hong Kong Stock Connect Medical Mixed are targeting innovative pharmaceuticals [2] Group 3: Industry Trends - The rapid development of technologies such as AI, biomedicine, and blockchain is reshaping the integration of technology, industry, and finance, as highlighted by the China Securities Regulatory Commission [2] - Fund managers express confidence in the ongoing transformation driven by AI and the potential for growth in China's manufacturing and new consumption sectors due to structural changes in the economy and population [2] Group 4: Innovation in Pharmaceuticals - The innovation drug sector is expected to perform well due to a combination of fundamental breakthroughs, policy support, and valuation recovery, according to industry experts [3] - Domestic innovative drug companies are seen to have advantages in clinical research speed and R&D costs, which are expected to drive rapid development in the sector [3]